Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label study to evaluate the effect of drug-drug interaction on the outcomes of the Cannabidiol (Epidiolex®) treatment in patients with Epilepsy

Trial Profile

An Open-label study to evaluate the effect of drug-drug interaction on the outcomes of the Cannabidiol (Epidiolex®) treatment in patients with Epilepsy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary) ; Clobazam; Eslicarbazepine acetate; Rufinamide; Topiramate; Zonisamide
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2018 New trial record
    • 27 Apr 2018 Results assessing changes in seizure frequency (SF) and severity (Chalfont Seizure Severity Scale; CSSS) and durability of the response to cannabidiol presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top